NECFA
BRNS

New England Capital Financial Advisors’s Barinthus Biotherapeutics BRNS Stock Holding History

New England Capital Financial Advisors’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$42 – 424
2025
Q2 		$42 Hold
45
– – ﹤0.01% 416
2025
Q1 		$44 Sell
45
-59
-57% -$61 ﹤0.01% 388
2024
Q4 		$126 Hold
104
– – ﹤0.01% 399
2024
Q3 		$124 Hold
104
– – ﹤0.01% 387
2024
Q2 		$146 Hold
104
– – ﹤0.01% 379
2024
Q1 		$248 Hold
104
– – ﹤0.01% 378
2023
Q4 		$384 Hold
104
– – ﹤0.01% 369
2023
Q3 		$322 Hold
104
– – ﹤0.01% 367
2023
Q2 		$215 Hold
104
– – ﹤0.01% 372
2023
Q1 		$233 Hold
104
– – ﹤0.01% 414
2022
Q4 		$282 Buy
+104
New +$265 ﹤0.01% 410

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

New England Capital Financial Advisors's BRNS Position: Q3 2025 in Review

New England Capital Financial Advisors sold out of Barinthus Biotherapeutics (BRNS) in Q3 2025, closing a stake of 45 shares — an estimated $42 sold.

New England Capital Financial Advisors first reported a position in BRNS in Q4 2022 and held it in 11 quarters. The position peaked at $384 in Q4 2023. 15 funds tracked by Wall St. Rank hold BRNS as of Q3 2025.

  • New England Capital Financial Advisors reported no remaining Barinthus Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • New England Capital Financial Advisors sold 45 Barinthus Biotherapeutics shares in Q3 2025, an estimated $42.
  • New England Capital Financial Advisors first reported a position in Barinthus Biotherapeutics in Q4 2022 and held it in 11 quarters.
  • New England Capital Financial Advisors's Barinthus Biotherapeutics position peaked at $384 in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2025.

Based on New England Capital Financial Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.